<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> proteins (IAPs) inhibit <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by binding specific caspases, and possibly by other mechanisms </plain></SENT>
<SENT sid="1" pm="."><plain>Eight IAPs have been identified in humans, of which cIAP1, cIAP2, and XIAP are well known </plain></SENT>
<SENT sid="2" pm="."><plain>IAPs are being investigated as potential treatment targets in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: cIAP1, cIAP2, and XIAP were assessed in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines, 240 B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, and 40 Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> IAPs were expressed in most NHL and <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>In NHL <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, cIAP1 was expressed in 174 (73%), cIAP2 in 115 (48%), and XIAP in 37 (15%) </plain></SENT>
<SENT sid="6" pm="."><plain>cIAP1 was positive in <z:hpo ids='HP_0000001'>all</z:hpo> precursor B-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> (LBL) and nodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>), over 90% of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), and approximately 50% to 60% of <z:mp ids='MP_0009440'>myeloma</z:mp>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005508'>Waldenstrom macroglobulinemia</z:hpo> (LPL/WM), small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/ <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL), extranodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of mucosa associated lymphoid tissue (MALT-<z:hpo ids='HP_0002665'>lymphoma</z:hpo>), splenic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>, and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>cIAP2 was positive in <z:hpo ids='HP_0000001'>all</z:hpo> MALT-<z:hpo ids='HP_0002665'>lymphoma</z:hpo>, over 90% of precursor B-cell LBL (94%), most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> (75%), LPL/WM (71%), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL (67%), and approximately 40% to 60% of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:mp ids='MP_0009440'>myeloma</z:mp>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>XIAP was positive most cases of precursor B-cell LBL (57%) and approximately 30% to 40% of nodal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, cIAP1 was positive in 30 (75%), cIAP2 in 27 (68%), and XIAP in 23 (58%), and did not correlate with histologic type </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Differential expression of IAPs in B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> suggests differences in pathogenesis that may have implications for novel treatment strategies targeting IAPs </plain></SENT>
</text></document>